Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
103 hedge funds and large institutions have $73.1M invested in Sanofi Contingent Value Rights in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3% less funds holding
Funds holding: 106 → 103 (-3)
9% less capital invested
Capital invested by funds: $80.4M → $73.1M (-$7.35M)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$2.73M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$295K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$65.3K |
| 4 |
Goldman Sachs
New York
|
+$45.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BMO
Beck Mack & Oliver
New York
|
-$174K |
| 2 |
CI
Cowen Inc
New York
|
-$30K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.1K |
| 4 |
MCM
Mainstay Capital Management
Grand Blanc,
Michigan
|
-$14K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$9K |
GCVRZ Hedge Fund Activity: Q4 2018 in Review
103 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2018, worth a combined $73.1M — down 9.1% from $80.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GCVRZ and 8 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 11 added.
The largest buyer was Stonehill Capital Management, adding an estimated $2.73M. The largest seller was Beck Mack & Oliver, exiting entirely with an estimated $174K sold.
- 103 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2018, down from 106 in Q3 2018.
- Funds reported $73.1M of Sanofi Contingent Value Rights stock for Q4 2018, down 9.1% quarter-over-quarter.
- 8 funds opened new Sanofi Contingent Value Rights positions in Q4 2018 and 11 closed out, a net change of -3 holders.
- The largest Sanofi Contingent Value Rights buyer in Q4 2018 was Stonehill Capital Management, an estimated $2.73M added.
- The largest Sanofi Contingent Value Rights seller in Q4 2018 was Beck Mack & Oliver, an estimated $174K sold.
Based on aggregated 13F filings for Q4 2018.